Celcuity Inc
CELCHealthcare|Biotechnology|USA
$107.58
-5.93 (-5.22%)
Tangible Book
$1.11
Earnings Power
$1.12
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | Breast Cancer | P3 | Active | 701 | RCT, Open-label | Gedatolisib, Palbociclib, Fulvestrant, Alpelisib |
| NCT06757634 Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Breast Cancer | P3 | Recruiting | 1,180 | RCT, Open-label | Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole |
| NCT06190899 Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | P1P2 | Recruiting | 54 | RCT, Open-label | Gedatolisib, Darolutamide |
| NCT03911973 Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | TNBC - Triple-Negative Breast Cancer | P1P2 | Active | 37 | Open-label | Gedatolisib, Talazoparib |
| NCT03675893 RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | Endometrial Cancer | P2 | Recruiting | 110 | Open-label | Letrozole, Abemaciclib, LY3023414, Metformin, Gedatolisib |
| NCT03812393 Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | Triple Negative Breast Cancer, Early-stage Breast Cancer | P2 | Unknown | 27 | Open-label | Neratinib |
| NCT03412643 Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | HER2-negative Breast Cancer | P2 | Unknown | 64 | Open-label | Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab |
| NCT05243641 Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | Metastatic Breast Cancer, Breast Cancer | P1P2 | Terminated | 10 | Open-label | Neratinib, Capmatinib |
| NCT04901299 Fulvestrant + Neratinib In Breast Cancer | Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer | P2 | Withdrawn | — | Open-label | NERATINIB, FULVESTRANT |
| NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | Breast Cancer | P1 | Completed | 141 | Open-label | Gedatolisib, Palbociclib, Letrozole, Fulvestrant |
| NCT05134922 Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 | Breast Neoplasm Malignant Female | AVAILABLE | — | — | Gedatolisib |